Clinical trial · Observational
Diagnostic and Prognostic Accuracy of Gold Nanoparticles in Salivary Gland Tumours
Gold Nanoparticles as Novel Biomarkers for Cancer Stem Cells in Salivary Gland Tumors: A Diagnostic and Prognostic Accuracy Study
NCT04907422CI-TRIAL-00053612completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Nano-based diagnostic tool can provide promising highly sensitive, specific biomarker for early detection and treatment of salivary gland tumours compared to non-conjugated biomarkers and in turn improves patient prognosis and outcome.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma Ex Pleomorphic Adenoma of Salivary Glands | — | UNRESOLVED | — |
| Pleomorphic Adenoma of Salivary Glands | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CD24-Gold Nanocomposite expression using Real-time quantitative polymerase chain reaction | Diagnostic Test | — | UNRESOLVED |
| non-conjugated CD24 expression using Real-time quantitative polymerase chain reaction | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- CXPA group
- description
- carcinoma ex pleomorphic adenoma of major and minor salivary glands.
- interventionNames
- Diagnostic Test: CD24-Gold Nanocomposite expression using Real-time quantitative polymerase chain reaction
- Diagnostic Test: non-conjugated CD24 expression using Real-time quantitative polymerase chain reaction
- label
- PA group
- description
- Benign pleomorphic adenoma of major and minor salivary glands.
- interventionNames
- Diagnostic Test: CD24-Gold Nanocomposite expression using Real-time quantitative polymerase chain reaction
- Diagnostic Test: non-conjugated CD24 expression using Real-time quantitative polymerase chain reaction
- label
- Control group
- description
- normal controls obtained from border of excision biopsy of mucocele in the lip mucosa of healthy individuals.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Benign PA of major and minor salivary glands (PA group), * CXPA of major and minor salivary glands (CXPA group). * Border of excision biopsy of mucocele in the lip mucosa of healthy individuals used as normal controls (Control group). * Surgical excision of tumors with no preoperative chemotherapy or radiotherapy. For parotid tumours partial or total parotidectomy, Surgery was performed with or without facial nerve preservation and the later was carried out commonly when the nerve was involved by tumour. For tumours in the other glands, complete surgical excision with the involved gland and the suspicious adjacent structures was performed. Exclusion Criteria: * All epithelial origin salivary gland tumours other than PA and CXPA. * All mesenchymal origin salivary gland tumours. * All inflammatory and cystic lesions of salivary glands. * Metastasis in salivary glands. * Patients received preoperative chemotherapy or radiotherapy.
References
Publications (2)
- DERIVEDKesharwani P, Ma R, Sang L, Fatima M, Sheikh A, Abourehab MAS, Gupta N, Chen ZS, Zhou Y. Gold nanoparticles and gold nanorods in the landscape of cancer therapy. Mol Cancer. 2023 Jun 21;22(1):98. doi: 10.1186/s12943-023-01798-8. PMID 37344887
- DERIVEDFarag AF, Hassabou NF. CD24-gold nanocomposite as promising and sensitive biomarker for cancer stem cells in salivary gland tumors. Nanomedicine. 2022 Nov;46:102598. doi: 10.1016/j.nano.2022.102598. Epub 2022 Sep 8. PMID 36089234